{
    "ticker": "NCNA",
    "name": "NantKwest, Inc.",
    "description": "NantKwest, Inc. is a clinical-stage immunotherapy company dedicated to the development of innovative therapies for the treatment of cancer and other diseases through the use of natural killer (NK) cell technology. Founded in 2015, NantKwest aims to harness the power of the immune system to fight cancer and other diseases by leveraging its proprietary NK cell platform. The company's lead product candidates include NK cell therapies designed to target various tumors, with a focus on solid tumors and hematologic malignancies. NantKwest has developed a unique approach to manufacturing and delivering NK cells, which allows for a scalable and effective treatment process. The company is actively engaged in clinical trials to evaluate the safety and efficacy of its therapies, and it collaborates with leading research institutions and healthcare providers to advance its mission. NantKwest is committed to addressing significant unmet medical needs in oncology and other therapeutic areas, and its innovative approach represents a promising advancement in the field of immuno-oncology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Los Angeles, California, USA",
    "founded": "2015",
    "website": "https://www.nantkwest.com",
    "ceo": "Patrick Soon-Shiong",
    "social_media": {
        "twitter": "https://twitter.com/NantKwest",
        "linkedin": "https://www.linkedin.com/company/nantkwest/"
    },
    "investor_relations": "https://investors.nantkwest.com",
    "key_executives": [
        {
            "name": "Patrick Soon-Shiong",
            "position": "CEO"
        },
        {
            "name": "Richard D. Wender",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapy",
            "products": [
                "NK Cell Therapy for Solid Tumors",
                "NK Cell Therapy for Hematologic Malignancies"
            ]
        }
    ],
    "seo": {
        "meta_title": "NantKwest, Inc. | Advancing Immunotherapy for Cancer Treatment",
        "meta_description": "Explore NantKwest, Inc., a leader in immunotherapy focused on natural killer cell technology for innovative cancer treatments. Learn about their mission and therapies.",
        "keywords": [
            "NantKwest",
            "Immunotherapy",
            "Natural Killer Cells",
            "Cancer Treatment",
            "Oncology",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is NantKwest known for?",
            "answer": "NantKwest is known for its innovative NK cell therapies aimed at treating cancer."
        },
        {
            "question": "Who is the CEO of NantKwest?",
            "answer": "Patrick Soon-Shiong is the CEO of NantKwest, Inc."
        },
        {
            "question": "Where is NantKwest headquartered?",
            "answer": "NantKwest is headquartered in Los Angeles, California, USA."
        },
        {
            "question": "What are NantKwest's main products?",
            "answer": "NantKwest's main products include NK cell therapies for solid tumors and hematologic malignancies."
        },
        {
            "question": "When was NantKwest founded?",
            "answer": "NantKwest was founded in 2015."
        }
    ],
    "competitors": [
        "KITE",
        "CRSP",
        "PGEN",
        "ZIOP"
    ],
    "related_stocks": [
        "BMY",
        "JNJ",
        "AMGN",
        "GILD"
    ]
}